Quantbot Technologies LP Takes $355,000 Position in Biohaven Ltd. (NYSE:BHVN)

Quantbot Technologies LP acquired a new position in shares of Biohaven Ltd. (NYSE:BHVN) in the 4th quarter, HoldingsChannel reports. The fund acquired 9,508 shares of the company’s stock, valued at approximately $355,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Stifel Financial Corp boosted its holdings in Biohaven by 0.4% during the third quarter. Stifel Financial Corp now owns 6,509,261 shares of the company’s stock valued at $325,268,000 after acquiring an additional 28,684 shares during the period. Janus Henderson Group PLC lifted its position in shares of Biohaven by 5.6% during the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company’s stock worth $311,142,000 after purchasing an additional 328,099 shares during the last quarter. Geode Capital Management LLC increased its position in Biohaven by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company’s stock worth $85,696,000 after buying an additional 44,174 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after buying an additional 1,322,922 shares during the last quarter. Finally, ARS Investment Partners LLC boosted its position in shares of Biohaven by 1.0% in the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock valued at $38,871,000 after acquiring an additional 10,473 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $27.59 on Friday. Biohaven Ltd. has a 52-week low of $26.57 and a 52-week high of $55.72. The business has a fifty day moving average of $35.15 and a two-hundred day moving average of $41.32. The stock has a market cap of $2.82 billion, a PE ratio of -2.95 and a beta of 1.27.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price objective on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Morgan Stanley reduced their target price on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the stock a “buy” rating in a research report on Thursday, March 20th. Fourteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Biohaven currently has a consensus rating of “Buy” and an average target price of $62.77.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs purchased 32,700 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the acquisition, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. This represents a 1.43 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by company insiders.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.